Novartis Patent-Cliff Exposure & CMS Drug Spending Portfolio
Novartis (East Hanover, NJ): 123 reconciled FDA prescription therapies (40.9% 2025 to 2030 cliff risk), $14.00B 2024 CMS Part D & Medicaid spend, and 292 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | East Hanover, NJ |
| Reconciled FDA Portfolio Therapies | 123 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 40.9% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $14.00B |
| 2024 Medicare Part D Spend | $10.20B |
| 2024 Medicaid Spend | $3.79B |
| California HCAI SB 17 Filings | 292 WAC filings (max 28.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.